National Cancer Institute

Palliative care can be given to people at any stage of their disease to help manage their physical symptoms and emotional issues.

As more people with cancer use medical marijuana, oncologists face a deficit of data and feel ill-equipped to properly answer.

Hospitals big and small face multiple barriers in establishing and maintaining programs for adolescents and young adults with cancer.

No drugs are approved in the United States or Europe to treat wasting syndrome, so the results with ponsegromab are promising.

About 30% of eligible U.S. adults are not up to date with any type of recommended colorectal cancer screening.

Leiomyosarcoma is a malignant tumor of smooth muscle cells; it’s most common in the uterus, abdomen or pelvis.

Osteonecrosis of the jaw linked to bone-modifying drugs is not as rare as once thought; meds are used if cancer spreads to the bone.

False positives on a mammogram are apparent abnormalities that, after further evaluation, are found not to be cancer.

This discovery provides an opportunity for developing treatments that may potentially prevent breast cancer from spreading.

People taking Gleevec (imatinib) to treat certain gastrointestinal stromal tumors (GISTs) should continue until the disease gets worse.

An ancient virus-derived DNA fragment known as LTR10 can act as an “on switch” for a wide variety of cancers.

The decision marks the first time the agency has approved a treatment called a T-cell receptor (TCR) therapy for cancer.

Supporting work in all components of higher education is essential to the future of cancer research.

The idea is that as a person undergoes treatment, the engineered cancer cells don’t just survive, they thrive, quickly taking over the tumor

Two studies in mice show that adding chemotherapy to an experimental KRAS inhibitor greatly reduced pancreatic tumor growth and spread.

A Q&A with Stephanie Goff, MD, who specializes in developing and testing gene-engineered T-cell therapies, including CAR T treatments

In both trials, adding a JAK inhibitor to an immune checkpoint inhibitor shrank tumors in more than half of participants.